| Autor: |
Doukas J; Selective Genetics, Inc., San Diego, California 92121, USA. jdoukas@selectivegenetics.com, Blease K, Craig D, Ma C, Chandler LA, Sosnowski BA, Pierce GF |
| Jazyk: |
angličtina |
| Zdroj: |
Molecular therapy : the journal of the American Society of Gene Therapy [Mol Ther] 2002 May; Vol. 5 (5 Pt 1), pp. 517-27. |
| DOI: |
10.1006/mthe.2002.0579 |
| Abstrakt: |
Tissue repair is driven by migratory macrophages and fibroblasts that infiltrate injury sites and secrete growth factors. We now report the enhancement of skeletal muscle repair by targeting transgene delivery to these repair cells using matrix-immobilized gene vectors. Plasmid and adenovirus vectors immobilized in collagen-gelatin admixtures were delivered to excisional muscle wounds, and when encoding either fibroblast growth factor-2 (FGF2) or FGF6 transgenes, produced early angiogenic responses that subsequently remodeled into arteriogenesis. FGF2 gene delivery enhanced the number of CD31(+) endothelial cells present at treatment sites > 6-fold by day 14, and muscular arteriole density up to 11-fold by day 21 (P<0.0001). Muscle repair was also enhanced, as FGF gene-treated wounds filled with regenerating myotubes expressing the marker CD56 (an average 20-fold increase in CD56 expression versus controls, P<0.0001). These responses required transfection of a threshold level of repair cells, achievable only in injured muscles, and were transgene-driven, as neither platelet-derived growth factor-B (PDGFB) gene nor FGF2 protein delivery produced equivalent responses. In conclusion, using biomatrices to direct gene delivery to repair cells allows for relatively complex regenerative processes such as arteriogenesis and myogenesis, and therefore represents a promising approach to treating injured and ischemic muscle. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
